1Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol [ J ].Nature, 1979,277 (5698): 665-667.
2Bergstralh DT, Ting JP, Bergstralh DT. Microtubule stabi- lizing agents: their molecular signaling consequences and the potential for enhancement by drug combination [J]. Cancer Treat Rev, 2006,32 (3): 166- 179.
3Ferlini C.Paclitaxel directly binds to Bcl-2 and functional- ly mimics activity of Nur77 [J] Cancer Res,2009, 69 (17) :6906-6914.
4Wang TH. Microtubule dysfunction induced by paclitaxel.initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and-independent pathways in ovarian cancer cells [ J ]. J Biol Chem, 1999,274 (12) :8208-8216.
5Blagosklonny MV, Schulte T, Nguyen P, et al.Taxol-in- duced apoptosis and phosphorylation of Bcl-2 protein in- volves c-Raf-1 and represents a novel c-Raf-1 signal trans- duction pathway[J]. Cancer Res ,1996,56 (8):1851-1854.
6Wang J. Kuiatse I. Lee AV, et al. Sustained c-Jun-NH2-ki- nase activity promotes epithelial- mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation [ J ]. Molec- ular Cancer Research, 2010,8 (2) :266-277.
7Shi Y, Liu X, Han EK, et al.Optimal classes of chemother- apeutic agents sensitized by specific small-molecule inhibi- tors ofakt in vitro and in vivo[J].Neoplasia, 2005,7( 11 ): 992-1000.
8Fukasawa K, Rulong S, Resau, J, et al.Overexpression of mos oncogene product in Swiss 3T3 cells induces apopto- sis preferentially during S-phase [J]. Oncogene, 1995, 10 (1):1-8.
9Ling YH, Yang Y, Tornos C. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells [J]. Cancer Res, 1998,58 (16) :3633-3640.
10Woods CM, Zhu J, McQueney PA, et al.Taxol-induced mi- totic block triggers rapid onset of a p53-independent apop- totic pathway[ J]. Mol Med, 1995,1 (5) :506-526.
3Smith EJ, Rothman MT. Antiproliferative coatings for the treatment of coronary heart disease:what are the targets and which are the tools? J Interv Cardiol, 2003, 16 (6): 475-483.
4Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet, 2003, 361 (9353): 247-249.
5Derntl M, Syeda B, Beran G, Schukro C, Denk S, Glogar D. Prevention of stent thrombosis following brachytherapy and implantation of drug-eluting stents. J Interv Cardiol, 2002, 15 (6): 477-483.
6Virmani R, Liistro F, Stankovic G, Dimario C, Montorfano M, Farb A, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation, 2002, 106 (21):2 649-651.
7Losordo DW, Isner JM, Diaz-Sandoval LJ. Endothelial recovery the next target in restenosis prevention. Circulation, 2003, 107 (21): 2 635-637.
8Axel DI, Riessen R, Athanasiadis A, Runge H, Koveker G, Karsch KR. Growth factor espression of human arterial smooth cells and endothelial cells in a transfilter coculture system. J Mol Cell Cardiol, 1997, 29 (11): 2 967-978.
9Spees JL, Olson SD, Ylostalo J, Lynch PJ, Smith J, Perry A, et al. Differentiation,cell fusion,and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci, 2003, 100 (5): 2 397-402.
10Frixione E. Recurring views on the structure and function of the cytoskeleton: a 300-year epic. Cell Motil Cytos, 2000, 46 (2): 73-94.
